Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,845 | 1 | 98.3% |
| Food and Beverage | $98.79 | 4 | 1.7% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $5,845 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $50.73 | 1 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $48.06 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $29.34 | 2 | Janssen Pharmaceuticals, Inc ($29.34) |
| 2018 | $5,845 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($5,845) |
| 2017 | $69.45 | 2 | Merck Sharp & Dohme Corporation ($50.73) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/11/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/09/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/01/2018 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $5,845.48 | Research |
| Study: Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI1-GII4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years | ||||||
| 12/14/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/06/2017 | Merck Sharp & Dohme Corporation | NEXPLANON (Drug) | Food and Beverage | In-kind items and services | $50.73 | General |
| Category: WOMENS HEALTH | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI1-GII4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years | Takeda Pharmaceuticals U.S.A., Inc. | $5,845 | 1 |
About Dr. Sylvia Becker-Dreps, MD
Dr. Sylvia Becker-Dreps, MD is a Family Medicine healthcare provider based in Carrboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588768055.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sylvia Becker-Dreps, MD has received a total of $5,944 in payments from pharmaceutical and medical device companies, with $29.34 received in 2019. These payments were reported across 5 transactions from 3 companies. The most common payment nature is "" ($5,845).
Practice Information
- Specialty Family Medicine
- Location Carrboro, NC
- Active Since 09/12/2006
- Last Updated 03/13/2013
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1588768055
Products in Payments
- NEXPLANON (Drug) $50.73
- XARELTO (Drug) $48.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Carrboro
Yulia Neyman, D.o, D.O
Family Medicine — Payments: $5,071
James Manor, Md, MD
Family Medicine — Payments: $1,285
Bruce Wilks, Md, MD
Family Medicine — Payments: $594.98
Dr. Kathleen Shapley-Quinn, Md, MD
Family Medicine — Payments: $220.06
Dr. Ariana Pancaldo, M.d, M.D
Family Medicine — Payments: $83.34
Mary Hampe, Md, MD
Family Medicine — Payments: $47.45